Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26329334.
- Also identified by DOI 10.3899/jrheum.150193.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the effects of changing inflammation on lipid levels in ankylosing spondylitis. In a cohort of 230 patients, lipid levels were measured at baseline and after 52 weeks of treatment with tumor necrosis factor-α-blocking agents (anti-TNF). Total cholesterol (TC; +4.6%), low-density lipoprotein cholesterol (+4.3%), and high-density lipoprotein cholesterol (HDL-C; +3.7%) increased upon treatment. Changes were most evident in patients with substantial reduction in inflammatory levels (TC +8.2% vs +1.6% and HDL-C +8.3% vs +2.2% in patients with C-reactive protein ≥ 10 mg/l normalizing upon treatment vs CRP < 10 mg/l throughout treatment period). Anti-TNF therapy results in lipid changes mostly when inflammation is appreciably modified.
Medical subject headings
- Adalimumab
- C-Reactive Protein
- Cholesterol, LDL
- Etanercept
- Inflammation
- Spondylitis, Ankylosing